Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BESREMi (ropeginterferon alfa-2b) is a long-acting, mono-pegylated proline interferon. It is administered once every 2 weeks initially, or up to every 4 weeks after stabilization of blood values. BESREMi is designed to be self-administered subcutaneously...
Brand Name : Besremi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 13, 2022
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BESREMi (Ropeginterferon alfa-2b) is long-acting, mono-pegylated proline interferon, unique pharmacokinetic properties new level of tolerability, designed to be conveniently self-administered subcutaneously with pen once every two weeks, or up to monthly...
Brand Name : Besremi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 13, 2022
Lead Product(s) : Ropeginterferon-Alfa-2b
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?